MRK · Merck & Co., Inc.
$120.872026-05-17Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Bull
$455
+276.3% vs market
Base · active
$151
+25.1% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($143 · $455) Analysts Range ($100 · $150) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $48.7B | — | 27.9% | 11.0% | $12.1B | −$18.6B | −$6.6B | 3.1% | — | 11.2% | $107.6B | $5.24 | — |
| 2022.Q4 | $59.3B | 21.7% | 31.7% | 11.7% | $16.6B | −$4.0B | $12.6B | 5.1% | — | 15.1% | $112.5B | $5.84 | — |
| 2023.Q4 | $60.1B | 1.4% | 5.1% | 45.0% | $1.7B | −$14.8B | −$13.1B | 4.9% | — | 1.2% | $175.7B | $0.15 | — |
| 2024.Q4 | $64.2B | 6.7% | 32.4% | 14.1% | $17.9B | −$7.5B | $10.4B | 5.7% | — | 11.5% | $134.6B | $6.88 | — |
| 2025.Q4 | $65.0B | 1.3% | 42.3% | 13.3% | $23.9B | −$16.0B | $7.8B | 5.4% | — | 17.1% | $143.8B | $7.34 | 10.9 |
| italics below = DCF projection · 10yr Rev CAGR: 5.1% |
| 2026.Q4 | $66.8B | +2.7% | 42.4% | 14.0% | $24.4B | −$12.1B | $12.3B | 5.6% | $11.6B | 16.3% | $155.9B | $9.53 | 12.7 |
| 2027.Q4 | $70.2B | +5.2% | 61.5% | 14.7% | $36.9B | −$14.1B | $22.8B | 5.9% | $20.4B | 22.6% | $170.0B | $14.43 | 8.4 |
| 2028.Q4 | $74.9B | +6.7% | 55.4% | 15.3% | $35.2B | −$13.4B | $21.7B | 6.2% | $18.3B | 19.9% | $183.4B | $13.75 | 8.8 |
| 2029.Q4 | $79.7B | +6.3% | 61.2% | 16.0% | $41.0B | −$21.7B | $19.3B | 6.5% | $15.2B | 21.1% | $205.1B | $16.02 | 7.5 |
| 2030.Q4 | $84.4B | +6.0% | 61.2% | 16.7% | $43.1B | −$20.0B | $23.1B | 6.8% | $17.1B | 20.0% | $225.1B | $16.84 | 7.2 |
|
| Term. Yr+ | $111.3B | 4.1% | 34.6% | 20.0% | $30.8B | −$12.7B | $18.1B | 8.6% | $205.1B | 9.9% | — | — | — |
Active scenario IV: $151 (+25.1% vs market)